DeepMed Research

Hutchmed Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $2.9B

Website

Clinical Trials

Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects

Phase 1

Active, not recruiting

Conditions: Mass Balance Study

Interventions: Drug: 100 µCi [14C] HMPL-306

First Posted Date: 2024-11-04

Last Posted Date: 2025-03-17

Lead Sponsor: Hutchmed

Target Recruit Count: 6

Registration Number: NCT06671873

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, China

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 2

Recruiting

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: HMPL-760 planned dose 1
Drug: R-GemOx
Drug: HMPL-760 placebo planned dose 1
Drug: HMPL-760 planned dose 2
Drug: HMPL-760 placebo planned dose 2

First Posted Date: 2024-09-19

Last Posted Date: 2024-11-21

Lead Sponsor: Hutchmed

Target Recruit Count: 60

Registration Number: NCT06601504

Locations: 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 20 locations

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3

Recruiting

Conditions: Advanced Endometrial Cancer

Interventions: Drug: fruquintinib
Drug: paclitaxel
Biological: sintilimab
Drug: doxorubicin

First Posted Date: 2024-09-04

Last Posted Date: 2025-01-07

Lead Sponsor: Hutchmed

Target Recruit Count: 412

Registration Number: NCT06584032

Locations: 🇨🇳
Beijing Obstetrics and Gynecology Hospital, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Phase 1

Recruiting

Conditions: Hematological Malignancies

Interventions: Drug: HMPL-506

First Posted Date: 2024-04-26

Last Posted Date: 2025-03-07

Lead Sponsor: Hutchmed

Target Recruit Count: 132

Registration Number: NCT06387082

Locations: 🇨🇳
Tianjin People's Hospital, Tianjin, China
🇨🇳
Wuhan Union Hospital of China, Wuhan, China
🇨🇳
Xiangya Hospital of Central South University, Changsha, China

and more 9 locations

A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia

Phase 3

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: HMPL-306 Regimen
Drug: Salvage Chemotherapy Regimen

First Posted Date: 2024-04-26

Last Posted Date: 2024-05-30

Lead Sponsor: Hutchmed

Target Recruit Count: 316

Registration Number: NCT06387069

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Drug: Nab-paclitaxel Plus Gemcitabine
Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine

First Posted Date: 2024-04-12

Last Posted Date: 2024-05-14

Lead Sponsor: Hutchmed

Target Recruit Count: 482

Registration Number: NCT06361888

Locations: 🇨🇳
Nanjing Tianyinshan Hospital, Nanjing, Jiang Su, China
🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Phase 1

Recruiting

Conditions: Blood Platelet Disorder
Immune System Diseases
Skin Manifestations
Thrombocytopenia
Immune Thrombocytopenia
Autoimmune Diseases
Hemorrhage
Hematologic Diseases
Primary Immune Thrombocytopenia
ITP - Immune Thrombocytopenia

Interventions: Drug: HMPL-523

First Posted Date: 2024-03-04

Last Posted Date: 2024-08-15

Lead Sponsor: Hutchmed

Target Recruit Count: 48

Registration Number: NCT06291415

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Washington (UW) Medical Center, Seattle, Washington, United States
🇦🇺
The Perth Blood Institute (PBI) Hollywood Specialist Centre, West Perth, Western Australia, Australia

and more 25 locations

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Phase 1

Completed

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: HMPL-453
Drug: Rabeprazole

First Posted Date: 2023-07-05

Last Posted Date: 2023-09-06

Lead Sponsor: Hutchmed

Target Recruit Count: 24

Registration Number: NCT05930119

Locations: 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: HMPL-415S1

First Posted Date: 2023-06-02

Last Posted Date: 2023-07-21

Lead Sponsor: Hutchmed

Target Recruit Count: 81

Registration Number: NCT05886374

Locations: 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

Phase 1

Completed

Conditions: Imumune Thrombocytopenia(ITP) Human Mass Balance

Interventions: Drug: HMPL-523
Drug: 150 µCi [14C]HMPL-523

First Posted Date: 2023-03-23

Last Posted Date: 2024-07-16

Lead Sponsor: Hutchmed

Target Recruit Count: 6

Registration Number: NCT05781906

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy